Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Poplin E
Wasan H
Rolfe L
Raponi M
Ikdahl T
Bondarenko I
Davidenko I
Bondar V
Garin A
Boeck S
Ormanns S
Heinemann V
Evans TR
Andersson R
Hahn H
Picozzi V
Dicker A
Mann E
Voong C
Kaur P
Isaacson J
Allen A.
BASSI, Claudio

Publication date

January 2013

Abstract

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Extracted data

We use cookies to provide a better user experience.

Data Protection

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Poplin E
Wasan H
Rolfe L
Raponi M
Ikdahl T
Bondarenko I
Davidenko I
Bondar V
Garin A
Boeck S
Ormanns S
Heinemann V
Evans TR
Andersson R
Hahn H
Picozzi V
Dicker A
Mann E
Voong C
Kaur P
Isaacson J
Allen A.
BASSI, Claudio

Open link

Publication date

January 2013

Abstract

Extracted data

Dalgleish, AG
Stebbing, J
Adamson, DJA
Arif, SS
Bidoli, P
Chang, D
Cheeseman, S
Diaz-Beveridge, R
Fernandez-Martos, C
Glynne-Jones, R
Granetto, C
Massuti, B
McAdam, K
McDermott, R
Munoz Martin, AJ
Papamichael, D
Pazo-Cid, R
Vieitez, JM
Zaniboni, A
Carroll, KJ
Wagle, S
Gaya, A
Mudan, SS

July 2016

Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, firs...

Differential gemcitabine sensitivity in primary human pancreatic cancer cells and paired stellate cells is driven by heterogenous drug uptake and processing

Amrutkar, Manoj
Vethe, Nils Tore
Verbeke, Caroline Sophie
Aasrum, Monica
Vefferstad, Anette
Sántha, Petra
Gladhaug, Ivar Prydz

January 2020

Gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) is attributed to cancer cell-intri...

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma

Borbath, Ivan
Verbrugghe, L
Lai, Raymond
Gigot, Jean-François
Humblet, Yves
Piessevaux, Hubert
Sempoux, Christine

January 2012

BACKGROUND: Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance fo...

Poplin, Elizabeth
Wasan, Harpreet
Rolfe, Lindsey
Raponi, Mitch
Ikdahl, Tone
Bondarenko, Ihor
Davidenko, Irina
Bondar, Volodymyr
Garin, August
Boeck, Stefan
Ormanns, Steffen
Heinemann, Volker
Bassi, Claudio
Evans, T R Jeffrey
Andersson, Roland
Hahn, Hejin
Picozzi, Vince
Dicker, Adam
Mann, Elaina
Voong, Cynthia
Kaur, Paramjit
Isaacson, Jeff
Allen, Andrew

January 2013

Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibra...

Randomized, multicenter, phase 2 study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity

Poplin, E.
Wasan, H.
Rolfe, L.
Raponi, M.
Ikdahl, T.
Bodarenko, I.
Davidenko, I.
Bondar, V.
Garin, A.
Boeck, S.
Ormanns, S.
Heinemann, V.
Bassi, C.
Evans, T.R.J.
Andersson, R.
Hahn, H.
Picozzi, V.
Dicker, A.
Mann, E.
Voong, C.
Kaur, P.
Isaacson, J.
Allen, A.

December 2013

<b>Purpose</b> Gemcitabine requires transporter proteins to cross cell membranes. Low ex...

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.

Raffenne, Jerome
Nicolle, Rémy
Puleo, Francesco
Le Corre, Delphine
Boyez, Camille
Marechal, Raphaël
Emile, Jean François
Demetter, Pieter
Bardier, Armelle
Laurent Puig, Pierre
de Mestier, Louis
Paradis, Valérie
Couvelard, Anne
Vanlathem, Jean-Marie
Mackey, John R
Bachet, Jean-Baptiste
Svrcek, Magali
Cros, Jérôme

November 2019

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma ...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils O.
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Büchler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilib...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.

Aughton, K
Elander, NO
Evans, A
Jackson, R
Campbell, F
Costello, E
Halloran, CM
Mackey, JR
Scarfe, AG
Valle, JW
Carter, R
Cunningham, D
Tebbutt, NC
Goldstein, D
Shannon, J
Glimelius, B
Hackert, T
Charnley, RM
Anthoney, A
Lerch, MM
Mayerle, J
Palmer, DH
Büchler, MW
Ghaneh, P
Neoptolemos, JP
Greenhalf, W

November 2021

Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilib...

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

Greenhalf, William
Ghaneh, Paula
Neoptolemos, John P.
Palmer, Daniel H.
Cox, Trevor F.
Lamb, Richard F.
Garner, Elizabeth
Campbell, Fiona
Mackey, John R.
Costello, Eithne
Moore, Malcolm J.
Valle, Juan W.
Mcdonald, Alexander C.
Carter, Ross
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Dervenis, Christos
Glimelius, Bengt
Deakin, Mark
Charnley, Richard M.
Lacaine, François
Scarfe, Andrew G.
Middleton, Mark R.
Anthoney, Alan
Halloran, Christopher M.
Mayerle, Julia
Oláh, Attila
Jackson, Richard
Rawcliffe, Charlotte L.
Büchler, Markus W.
for the European Study Group for Pancreatic Cancer
SCARPA, Aldo
BASSI, Claudio

January 2014

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinom...

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Greenhalf, W
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Lamb, R
Garner, E
Campbell, F
Mackey, JR
Costello, E
Moore, M
Valle, J
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Lacaine, F
Scarfe, A
Middleton, MR
Anthoney, A

January 2014

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Buechler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Simple Summary: Recent clinical trials suggest that combination therapies that include either gemcit...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Buechler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Simple Summary: Recent clinical trials suggest that combination therapies that include either gemcit...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils O.
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Büchler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

November 2021

Simple Summary Recent clinical trials suggest that combination therapies that include eit...

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Dalgleish, AG
Stebbing, J
Adamson, DJA
Arif, SS
Bidoli, P
Chang, D
Cheeseman, S
Diaz-Beveridge, R
Fernandez-Martos, C
Glynne-Jones, R
Granetto, C
Massuti, B
McAdam, K
McDermott, R
Munoz Martin, AJ
Papamichael, D
Pazo-Cid, R
Vieitez, JM
Zaniboni, A
Carroll, KJ
Wagle, S
Gaya, A
Mudan, SS

July 2016

Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, firs...

Differential gemcitabine sensitivity in primary human pancreatic cancer cells and paired stellate cells is driven by heterogenous drug uptake and processing

Amrutkar, Manoj
Vethe, Nils Tore
Verbeke, Caroline Sophie
Aasrum, Monica
Vefferstad, Anette
Sántha, Petra
Gladhaug, Ivar Prydz

January 2020

Gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) is attributed to cancer cell-intri...

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma

Borbath, Ivan
Verbrugghe, L
Lai, Raymond
Gigot, Jean-François
Humblet, Yves
Piessevaux, Hubert
Sempoux, Christine

January 2012

BACKGROUND: Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance fo...

Poplin, Elizabeth
Wasan, Harpreet
Rolfe, Lindsey
Raponi, Mitch
Ikdahl, Tone
Bondarenko, Ihor
Davidenko, Irina
Bondar, Volodymyr
Garin, August
Boeck, Stefan
Ormanns, Steffen
Heinemann, Volker
Bassi, Claudio
Evans, T R Jeffrey
Andersson, Roland
Hahn, Hejin
Picozzi, Vince
Dicker, Adam
Mann, Elaina
Voong, Cynthia
Kaur, Paramjit
Isaacson, Jeff
Allen, Andrew

January 2013

Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibra...

Poplin, E.
Wasan, H.
Rolfe, L.
Raponi, M.
Ikdahl, T.
Bodarenko, I.
Davidenko, I.
Bondar, V.
Garin, A.
Boeck, S.
Ormanns, S.
Heinemann, V.
Bassi, C.
Evans, T.R.J.
Andersson, R.
Hahn, H.
Picozzi, V.
Dicker, A.
Mann, E.
Voong, C.
Kaur, P.
Isaacson, J.
Allen, A.

December 2013

<b>Purpose</b> Gemcitabine requires transporter proteins to cross cell membranes. Low ex...

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.

Raffenne, Jerome
Nicolle, Rémy
Puleo, Francesco
Le Corre, Delphine
Boyez, Camille
Marechal, Raphaël
Emile, Jean François
Demetter, Pieter
Bardier, Armelle
Laurent Puig, Pierre
de Mestier, Louis
Paradis, Valérie
Couvelard, Anne
Vanlathem, Jean-Marie
Mackey, John R
Bachet, Jean-Baptiste
Svrcek, Magali
Cros, Jérôme

November 2019

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma ...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils O.
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Büchler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilib...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.

Aughton, K
Elander, NO
Evans, A
Jackson, R
Campbell, F
Costello, E
Halloran, CM
Mackey, JR
Scarfe, AG
Valle, JW
Carter, R
Cunningham, D
Tebbutt, NC
Goldstein, D
Shannon, J
Glimelius, B
Hackert, T
Charnley, RM
Anthoney, A
Lerch, MM
Mayerle, J
Palmer, DH
Büchler, MW
Ghaneh, P
Neoptolemos, JP
Greenhalf, W

November 2021

Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilib...

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

Greenhalf, William
Ghaneh, Paula
Neoptolemos, John P.
Palmer, Daniel H.
Cox, Trevor F.
Lamb, Richard F.
Garner, Elizabeth
Campbell, Fiona
Mackey, John R.
Costello, Eithne
Moore, Malcolm J.
Valle, Juan W.
Mcdonald, Alexander C.
Carter, Ross
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Dervenis, Christos
Glimelius, Bengt
Deakin, Mark
Charnley, Richard M.
Lacaine, François
Scarfe, Andrew G.
Middleton, Mark R.
Anthoney, Alan
Halloran, Christopher M.
Mayerle, Julia
Oláh, Attila
Jackson, Richard
Rawcliffe, Charlotte L.
Büchler, Markus W.
for the European Study Group for Pancreatic Cancer
SCARPA, Aldo
BASSI, Claudio

January 2014

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinom...

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Greenhalf, W
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Lamb, R
Garner, E
Campbell, F
Mackey, JR
Costello, E
Moore, M
Valle, J
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Lacaine, F
Scarfe, A
Middleton, MR
Anthoney, A

January 2014

BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Buechler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Simple Summary: Recent clinical trials suggest that combination therapies that include either gemcit...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Buechler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

January 2021

Simple Summary: Recent clinical trials suggest that combination therapies that include either gemcit...

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

Aughton, Karen
Elander, Nils O.
Evans, Anthony
Jackson, Richard
Campbell, Fiona
Costello, Eithne
Halloran, Christopher M.
Mackey, John R.
Scarfe, Andrew G.
Valle, Juan W.
Carter, Ross
Cunningham, David
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Glimelius, Bengt
Hackert, Thilo
Charnley, Richard M.
Anthoney, Alan
Lerch, Markus M.
Mayerle, Julia
Palmer, Daniel H.
Büchler, Markus W.
Ghaneh, Paula
Neoptolemos, John P.
Greenhalf, William

November 2021

Simple Summary Recent clinical trials suggest that combination therapies that include eit...

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Dalgleish, AG
Stebbing, J
Adamson, DJA
Arif, SS
Bidoli, P
Chang, D
Cheeseman, S
Diaz-Beveridge, R
Fernandez-Martos, C
Glynne-Jones, R
Granetto, C
Massuti, B
McAdam, K
McDermott, R
Munoz Martin, AJ
Papamichael, D
Pazo-Cid, R
Vieitez, JM
Zaniboni, A
Carroll, KJ
Wagle, S
Gaya, A
Mudan, SS

July 2016

Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, firs...

Differential gemcitabine sensitivity in primary human pancreatic cancer cells and paired stellate cells is driven by heterogenous drug uptake and processing

Amrutkar, Manoj
Vethe, Nils Tore
Verbeke, Caroline Sophie
Aasrum, Monica
Vefferstad, Anette
Sántha, Petra
Gladhaug, Ivar Prydz

January 2020

Gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) is attributed to cancer cell-intri...

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma

Borbath, Ivan
Verbrugghe, L
Lai, Raymond
Gigot, Jean-François
Humblet, Yves
Piessevaux, Hubert
Sempoux, Christine

January 2012

BACKGROUND: Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance fo...

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Abstract

Extracted data

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Abstract

Extracted data

Related items

Related items